688117 圣诺生物
已收盘 10-30 15:00:00
资讯
新帖
简况
圣诺生物(688117)9月30日股东户数1.6万户,较上期增加39.8%
证券之星 · 10-28 18:33
圣诺生物(688117)9月30日股东户数1.6万户,较上期增加39.8%
股市必读:圣诺生物新发布《关于自愿披露特利加压素注射液获得药品注册证书的公告》
证券之星 · 10-19
股市必读:圣诺生物新发布《关于自愿披露特利加压素注射液获得药品注册证书的公告》
股市必读:圣诺生物新发布《关于自愿披露全资子公司获得出口欧盟原料药证明文件的公告》
证券之星 · 10-15
股市必读:圣诺生物新发布《关于自愿披露全资子公司获得出口欧盟原料药证明文件的公告》
股市必读:圣诺生物新发布《关于自愿披露全资子公司获得出口欧盟原料药证明文件的公告》
证券之星 · 10-14
股市必读:圣诺生物新发布《关于自愿披露全资子公司获得出口欧盟原料药证明文件的公告》
圣诺生物:眉山汇龙获欧盟原料药证明
格隆汇 · 10-13
圣诺生物:眉山汇龙获欧盟原料药证明
圣诺生物(688117)披露高级管理人员增持计划进展公告,10月08日股价下跌3.12%
证券之星 · 10-08
圣诺生物(688117)披露高级管理人员增持计划进展公告,10月08日股价下跌3.12%
股市必读:圣诺生物新发布《关于自愿披露全资子公司新增原料药品种取得药品生产许可证并通过GMP符合性检查的公告》
证券之星 · 10-08
股市必读:圣诺生物新发布《关于自愿披露全资子公司新增原料药品种取得药品生产许可证并通过GMP符合性检查的公告》
股市必读:圣诺生物新发布《关于自愿披露全资子公司新增原料药品种取得药品生产许可证并通过GMP符合性检查的公告》
证券之星 · 09-30
股市必读:圣诺生物新发布《关于自愿披露全资子公司新增原料药品种取得药品生产许可证并通过GMP符合性检查的公告》
遭FDA进口禁令,圣诺生物美国业务亮起红灯
新浪证券 · 09-24
遭FDA进口禁令,圣诺生物美国业务亮起红灯
圣诺生物(688117.SH)子公司圣诺制药被FDA纳入66-40名单说明
智通财经 · 09-22
圣诺生物(688117.SH)子公司圣诺制药被FDA纳入66-40名单说明
圣诺生物:为多肽类创新药研发提供药学研究和定制生产服务
证券之星 · 09-17
圣诺生物:为多肽类创新药研发提供药学研究和定制生产服务
圣诺生物:2026年营业收入增长率需达15.00%或20.00%
证券之星 · 09-17
圣诺生物:2026年营业收入增长率需达15.00%或20.00%
每周股票复盘:圣诺生物(688117)高管增持计划过半未实施
证券之星 · 09-13
每周股票复盘:圣诺生物(688117)高管增持计划过半未实施
股市必读:圣诺生物新发布《关于高级管理人员增持公司股份进展的公告》
证券之星 · 09-09
股市必读:圣诺生物新发布《关于高级管理人员增持公司股份进展的公告》
每周股票复盘:圣诺生物(688117)利那洛肽胶囊获注册证
证券之星 · 09-06
每周股票复盘:圣诺生物(688117)利那洛肽胶囊获注册证
股市必读:圣诺生物新发布《关于自愿披露利那洛肽胶囊获得药品注册证书的公告》
证券之星 · 09-04
股市必读:圣诺生物新发布《关于自愿披露利那洛肽胶囊获得药品注册证书的公告》
圣诺生物最新公告:醋酸特利加压素原料药获上市批准
证券之星 · 08-28
圣诺生物最新公告:醋酸特利加压素原料药获上市批准
每周股票复盘:圣诺生物(688117)Q2收入增71.62%,股东户数增14.2%
证券之星 · 08-23
每周股票复盘:圣诺生物(688117)Q2收入增71.62%,股东户数增14.2%
图解圣诺生物中报:第二季度单季净利润同比增长64.52%
证券之星 · 08-20
图解圣诺生物中报:第二季度单季净利润同比增长64.52%
圣诺生物(688117)披露2026年半年度报告,8月19日股价下跌1.65%
证券之星 · 08-19
圣诺生物(688117)披露2026年半年度报告,8月19日股价下跌1.65%
加载更多
公司概况
公司名称:
成都圣诺生物科技股份有限公司
所属行业:
医药制造业
上市日期:
2021-06-03
主营业务:
成都圣诺生物科技股份有限公司的主营业务是为国内外医药企业的多肽类创新药研发提供药学研究和定制生产服务,自主研发、生产和销售多肽类仿制药原料药和制剂产品以及多肽药物生产技术转让服务。公司的主要产品是多肽创新药CDMO服务、多肽原料药、多肽制剂产品、多肽类产品定制生产服务、多肽药物生产技术转让服务。公司在报告期内荣获“2026中国医药CDMO企业20强”。
发行价格:
17.90
{"stockData":{"symbol":"688117","market":"SH","secType":"STK","nameCN":"圣诺生物","latestPrice":14.35,"timestamp":1793343600000,"preClose":14.36,"halted":0,"volume":7420790,"delay":0,"changeRate":-0.0007,"floatShares":220000000,"shares":220000000,"eps":0.9146,"marketStatus":"已收盘","change":-0.01,"latestTime":"10-30 15:00:00","open":14.29,"high":15.06,"low":13.99,"amount":107000000,"amplitude":0.0745,"askPrice":14.36,"askSize":5,"bidPrice":14.35,"bidSize":65,"shortable":0,"etf":0,"ttmEps":0.9146,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1793583000000},"marketStatusCode":5,"adr":0,"adjPreClose":14.36,"symbolType":"stock_kcb","openAndCloseTimeList":[[1793323800000,1793331000000],[1793336400000,1793343600000]],"highLimit":15.8,"lowLimit":12.92,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":220340369,"isCdr":false,"pbRate":2.68,"roa":"--","peRate":15.689919,"roe":"15.12%","epsLYR":1,"committee":0.754647,"marketValue":3162000000,"turnoverRate":0.0337,"status":1,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2026-11-02。","afterMarket":{"amount":14350,"volume":1000,"close":14.35,"buyVolume":6800,"sellVolume":0,"time":1793345637746,"indexStatus":"已收盘 10-30 15:30:00","preClose":14.36},"floatMarketCap":3162000000},"requestUrl":"/m/hq/s/688117","defaultTab":"news","newsList":[{"id":"2678463753","title":"圣诺生物(688117)9月30日股东户数1.6万户,较上期增加39.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678463753","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678463753?lang=zh_cn&edition=full","pubTime":"2026-10-28 18:33","pubTimestamp":1793183615,"startTime":"0","endTime":"0","summary":"证券之星消息,近日圣诺生物披露,截至2026年9月30日公司股东户数为1.6万户,较6月30日增加4552.0户,增幅为39.8%。在化学制药行业个股中,圣诺生物股东户数低于行业平均水平,截至9月30日,化学制药行业平均股东户数为3.9万户。从股价来看,2026年6月30日至2026年9月30日,圣诺生物区间跌幅为31.34%,在此期间股东户数增加4552.0户,增幅为39.8%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102800040201.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688117","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676578269","title":"股市必读:圣诺生物新发布《关于自愿披露特利加压素注射液获得药品注册证书的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2676578269","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676578269?lang=zh_cn&edition=full","pubTime":"2026-10-19 01:55","pubTimestamp":1792346111,"startTime":"0","endTime":"0","summary":"公司公告汇总:全资子公司获特利加压素注射液《药品注册证书》,规格为8.5ml:0.85mg,注册分类为化学药品3类。公司公告汇总关于自愿披露特利加压素注射液获得药品注册证书的公告成都圣诺生物科技股份有限公司全资子公司成都圣诺生物制药有限公司近日收到国家药品监督管理局签发的特利加压素注射液《药品注册证书》,药品注册标准编号为YBH29202026,规格为8.5ml:0.85mg,注册分类为化学药品3类。该药品适用于治疗胃肠道和泌尿生殖系统出血症状。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101900000594.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688117","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675291213","title":"股市必读:圣诺生物新发布《关于自愿披露全资子公司获得出口欧盟原料药证明文件的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2675291213","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675291213?lang=zh_cn&edition=full","pubTime":"2026-10-15 01:40","pubTimestamp":1791999620,"startTime":"0","endTime":"0","summary":"公司公告汇总:全资子公司眉山汇龙药业获《出口欧盟原料药证明文件》,替尔泊肽原料药获准出口欧盟,有效期至2029年10月11日。公司公告汇总关于自愿披露全资子公司获得出口欧盟原料药证明文件的公告成都圣诺生物科技股份有限公司全资子公司眉山汇龙药业科技有限公司近日收到四川省药品监督管理局核发的《出口欧盟原料药证明文件》,证明其生产的替尔泊肽原料药符合中国GMP要求,且等同于欧盟、世界卫生组织及ICH Q7标准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101500001592.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688117","BK0239","FESXmain","FSXEmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675369521","title":"股市必读:圣诺生物新发布《关于自愿披露全资子公司获得出口欧盟原料药证明文件的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2675369521","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675369521?lang=zh_cn&edition=full","pubTime":"2026-10-14 01:27","pubTimestamp":1791912428,"startTime":"0","endTime":"0","summary":"公司公告汇总:全资子公司眉山汇龙药业获《出口欧盟原料药证明文件》,替尔泊肽原料药获准出口欧盟,有效期至2029年10月11日。公司公告汇总关于自愿披露全资子公司获得出口欧盟原料药证明文件的公告成都圣诺生物科技股份有限公司全资子公司眉山汇龙药业科技有限公司近日收到四川省药品监督管理局核发的《出口欧盟原料药证明文件》,证明其生产的替尔泊肽原料药符合中国GMP要求,且等同于欧盟、世界卫生组织及ICH Q7标准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101400001512.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688117","FSXEmain","BK0239","FESXmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675551093","title":"圣诺生物:眉山汇龙获欧盟原料药证明","url":"https://stock-news.laohu8.com/highlight/detail?id=2675551093","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675551093?lang=zh_cn&edition=full","pubTime":"2026-10-13 18:58","pubTimestamp":1791889118,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["688117","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673200379","title":"圣诺生物(688117)披露高级管理人员增持计划进展公告,10月08日股价下跌3.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2673200379","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673200379?lang=zh_cn&edition=full","pubTime":"2026-10-08 22:24","pubTimestamp":1791469459,"startTime":"0","endTime":"0","summary":"截至2026年10月8日收盘,圣诺生物报收于17.98元,较前一交易日下跌3.12%,最新总市值为39.62亿元。近日,圣诺生物披露《关于高级管理人员增持公司股份进展的公告》。公告显示,公司副总经理、董事会秘书饶进先生计划自2026年6月9日起6个月内增持公司股份,金额不低于800万元且不超过1000万元。截至2026年10月9日,饶进先生尚未实施增持,累计增持金额为0元。公司表示将继续推进增持计划,并及时履行信息披露义务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100800034578.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688117","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673014779","title":"股市必读:圣诺生物新发布《关于自愿披露全资子公司新增原料药品种取得药品生产许可证并通过GMP符合性检查的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2673014779","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673014779?lang=zh_cn&edition=full","pubTime":"2026-10-08 01:41","pubTimestamp":1791394869,"startTime":"0","endTime":"0","summary":"公司公告汇总关于自愿披露全资子公司新增原料药品种取得药品生产许可证并通过GMP符合性检查的公告成都圣诺生物科技股份有限公司全资子公司眉山汇龙药业科技有限公司收到四川省药品监督管理局核发的《药品生产许可证》及《药品GMP符合性检查告知书》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100800000954.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688117"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671249075","title":"股市必读:圣诺生物新发布《关于自愿披露全资子公司新增原料药品种取得药品生产许可证并通过GMP符合性检查的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2671249075","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671249075?lang=zh_cn&edition=full","pubTime":"2026-09-30 01:48","pubTimestamp":1790704098,"startTime":"0","endTime":"0","summary":"公司公告汇总关于自愿披露全资子公司新增原料药品种取得药品生产许可证并通过GMP符合性检查的公告成都圣诺生物科技股份有限公司全资子公司眉山汇龙药业科技有限公司近日收到四川省药品监督管理局核发的《药品生产许可证》及《药品GMP符合性检查告知书》。检查结论为符合药品GMP要求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026093000002157.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688117","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669946360","title":"遭FDA进口禁令,圣诺生物美国业务亮起红灯","url":"https://stock-news.laohu8.com/highlight/detail?id=2669946360","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669946360?lang=zh_cn&edition=full","pubTime":"2026-09-24 16:37","pubTimestamp":1790239020,"startTime":"0","endTime":"0","summary":"多肽CDMO企业圣诺生物子公司圣诺制药接受FDA现场检查之后,收到483观察表,随后被列入进口禁令名单。随后企业被纳入FDA进口禁令名单,产品出口美国将受到限制。截至目前公司尚未收到FDA警告信以及最终官方处置结论,但禁令已经客观形成约束。FDA的现场检查结果直接决定企业能否拿到海外订单。后续有两大看点,一是企业整改的进度,能否尽快消除FDA提出的各项缺陷、解除进口限制;二是海外客户信心是否发生动摇,会不会出现订单流失。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2026-09-24/doc-inisxnuv5179837.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688117","LABU","BK0239","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2669133921","title":"圣诺生物(688117.SH)子公司圣诺制药被FDA纳入66-40名单说明","url":"https://stock-news.laohu8.com/highlight/detail?id=2669133921","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669133921?lang=zh_cn&edition=full","pubTime":"2026-09-22 12:25","pubTimestamp":1790051123,"startTime":"0","endTime":"0","summary":"智通财经APP讯,圣诺生物 发布公告,公司全资子公司成都圣诺生物制药有限公司于2026年8月20日至2026年8月22日、2026年8月24日及2026年8月27日接受美国食品药品管理局检查组的现场检查。截止目前,经查询FDA官方网站,圣诺制药已于2026年9月19日被列入第 66-40号进口禁令名单;但公司除已收到上述FDA签发的Form FDA 483外,尚未收到美国FDA作出的官方行动指示结论,亦尚未收到 FDA 警告信。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1499200.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688117","BK0239","LABU","BK1574","BK1191","01477","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668968992","title":"圣诺生物:为多肽类创新药研发提供药学研究和定制生产服务","url":"https://stock-news.laohu8.com/highlight/detail?id=2668968992","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668968992?lang=zh_cn&edition=full","pubTime":"2026-09-17 17:09","pubTimestamp":1789636156,"startTime":"0","endTime":"0","summary":"证券之星消息,圣诺生物09月17日在投资者关系平台上答复投资者关心的问题。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091700026404.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688117"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668945968","title":"圣诺生物:2026年营业收入增长率需达15.00%或20.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2668945968","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668945968?lang=zh_cn&edition=full","pubTime":"2026-09-17 17:09","pubTimestamp":1789636154,"startTime":"0","endTime":"0","summary":"证券之星消息,圣诺生物09月17日在投资者关系平台上答复投资者关心的问题。圣诺生物回复:尊敬的投资者您好,公司《2026年限制性股票激励计划(草案)》及《2026年限制性股票激励计划实施考核管理办法》已于2026年7月8日在上海证券交易所网站披露。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091700026402.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688117"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667350779","title":"每周股票复盘:圣诺生物(688117)高管增持计划过半未实施","url":"https://stock-news.laohu8.com/highlight/detail?id=2667350779","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667350779?lang=zh_cn&edition=full","pubTime":"2026-09-13 02:42","pubTimestamp":1789238533,"startTime":"0","endTime":"0","summary":"截至2026年9月11日收盘,圣诺生物报收于22.37元,较上周的23.59元下跌5.17%。本周,圣诺生物9月8日盘中最高价报23.89元。截至2026年9月9日,增持计划实施期限已过半,饶进先生尚未增持公司股份,累计增持金额为0元。本次增持计划可能因资本市场变化等因素存在无法实施的风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091300000734.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688117"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666905372","title":"股市必读:圣诺生物新发布《关于高级管理人员增持公司股份进展的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2666905372","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666905372?lang=zh_cn&edition=full","pubTime":"2026-09-09 02:56","pubTimestamp":1788893773,"startTime":"0","endTime":"0","summary":"公司公告汇总关于高级管理人员增持公司股份进展的公告成都圣诺生物科技股份有限公司副总经理、董事会秘书饶进先生计划自2026年6月9日起6个月内增持公司股份,金额不低于800万元且不超过1000万元。截至2026年9月9日,增持计划实施期限已过半,饶进先生尚未增持公司股份,累计增持金额为0元。饶进先生对公司发展前景保持信心,认可长期投资价值,后续将继续按计划实施增持。本次增持计划可能因资本市场变化等因素存在无法实施的风险。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090900002924.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688117","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665936668","title":"每周股票复盘:圣诺生物(688117)利那洛肽胶囊获注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2665936668","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665936668?lang=zh_cn&edition=full","pubTime":"2026-09-06 03:28","pubTimestamp":1788636491,"startTime":"0","endTime":"0","summary":"截至2026年9月4日收盘,圣诺生物报收于23.59元,较上周的23.93元下跌1.42%。本周,圣诺生物9月4日盘中最高价报24.34元。8月31日盘中最低价报23.35元。圣诺生物当前最新总市值51.98亿元,在化学制药板块市值排名88/149,在两市A股市值排名3097/5214。公司利那洛肽原料药已完成美国FDA DMF备案。此次获批有助于丰富公司产品管线,提升在消化道领域的市场竞争力。具体销售情况受国家政策、市场环境等因素影响,存在不确定性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090600001163.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688117"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664057208","title":"股市必读:圣诺生物新发布《关于自愿披露利那洛肽胶囊获得药品注册证书的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2664057208","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664057208?lang=zh_cn&edition=full","pubTime":"2026-09-04 01:29","pubTimestamp":1788456551,"startTime":"0","endTime":"0","summary":"截至2026年9月3日收盘,圣诺生物报收于23.86元,上涨0.25%,换手率2.02%,成交量4.46万手,成交额1.06亿元。公司公告汇总关于自愿披露利那洛肽胶囊获得药品注册证书的公告成都圣诺生物科技股份有限公司全资子公司成都圣诺生物制药有限公司近日收到国家药品监督管理局签发的利那洛肽胶囊《药品注册证书》,药品注册标准编号为YBH25592026,规格为290μg,注册分类为化学药品4类。公司利那洛肽原料药已完成美国FDA DMF备案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090400002022.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688117"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662535067","title":"圣诺生物最新公告:醋酸特利加压素原料药获上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2662535067","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662535067?lang=zh_cn&edition=full","pubTime":"2026-08-28 19:24","pubTimestamp":1787916281,"startTime":"0","endTime":"0","summary":"圣诺生物(688117.SH)公告称,公司全资子公司成都圣诺生物制药有限公司近日收到国家药监局签发的醋酸特利加压素原料药《化学原料药上市申请批准通知书》。该药品主要用于收缩血管和抗出血,适用于胃肠道和泌尿生殖系统出血。此次获批将进一步丰富公司原料药产品线,优化产业布局,但具体销售情况受政策及市场环境影响,存在不确定性。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800045232.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688117"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661211630","title":"每周股票复盘:圣诺生物(688117)Q2收入增71.62%,股东户数增14.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661211630","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661211630?lang=zh_cn&edition=full","pubTime":"2026-08-23 01:34","pubTimestamp":1787420052,"startTime":"0","endTime":"0","summary":"截至2026年8月21日收盘,圣诺生物报收于25.79元,较上周的27.03元下跌4.59%。本周,圣诺生物8月19日盘中最高价报28.37元。股本股东变化股东户数变动截至2026年6月30日,圣诺生物股东户数为1.14万户,较3月31日增加1422.0户,增幅14.2%。业绩披露要点财务报告2026年上半年,圣诺生物主营收入5.07亿元,同比上升50.27%;归母净利润1.35亿元,同比上升51.98%;扣非净利润1.34亿元,同比上升50.19%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082300000180.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688117","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660380427","title":"图解圣诺生物中报:第二季度单季净利润同比增长64.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660380427","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660380427?lang=zh_cn&edition=full","pubTime":"2026-08-20 01:25","pubTimestamp":1787160317,"startTime":"0","endTime":"0","summary":"证券之星消息,圣诺生物2026年中报显示,上半年度公司主营收入5.07亿元,同比上升50.27%;归母净利润1.35亿元,同比上升51.98%;扣非净利润1.34亿元,同比上升50.19%;其中2026年第二季度,公司单季度主营收入2.63亿元,同比上升71.62%;单季度归母净利润6883.18万元,同比上升64.52%;单季度扣非净利润6850.72万元,同比上升64.95%;负债率44.8%,投资收益3.18万元,财务费用1044.68万元,毛利率58.73%。财报数据概要请见下图:本文数据来源于圣诺生物2026年中报,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082000001558.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688117"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660544429","title":"圣诺生物(688117)披露2026年半年度报告,8月19日股价下跌1.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660544429","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660544429?lang=zh_cn&edition=full","pubTime":"2026-08-19 22:10","pubTimestamp":1787148624,"startTime":"0","endTime":"0","summary":"截至2026年8月19日收盘,圣诺生物报收于26.9元,较前一交易日下跌1.65%,最新总市值为59.27亿元。该股当日开盘27.31元,最高28.37元,最低26.5元,成交额达3.97亿元,换手率为6.6%。近日,成都圣诺生物科技股份有限公司披露2026年半年度报告摘要。经营活动产生的现金流量净额为87,225,669.48元,同比增长6.82%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081900042964.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688117"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1793405925453,"stockEarnings":[{"period":"1week","weight":-0.0754},{"period":"1month","weight":-0.2268},{"period":"3month","weight":-0.3698},{"period":"6month","weight":-0.4577},{"period":"1year","weight":-0.4672},{"period":"ytd","weight":-0.4631}],"compareEarnings":[{"period":"1week","weight":-0.0248},{"period":"1month","weight":-0.0633},{"period":"3month","weight":-0.0609},{"period":"6month","weight":-0.1248},{"period":"1year","weight":-0.0973},{"period":"ytd","weight":-0.0932}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"成都圣诺生物科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"15988人(较上一季度增加39.80%)","perCapita":"13781股","listingDate":"2021-06-03","address":"四川省成都市大邑县大安路98号","registeredCapital":"22034万元","survey":" 成都圣诺生物科技股份有限公司的主营业务是为国内外医药企业的多肽类创新药研发提供药学研究和定制生产服务,自主研发、生产和销售多肽类仿制药原料药和制剂产品以及多肽药物生产技术转让服务。公司的主要产品是多肽创新药CDMO服务、多肽原料药、多肽制剂产品、多肽类产品定制生产服务、多肽药物生产技术转让服务。公司在报告期内荣获“2026中国医药CDMO企业20强”。","listedPrice":17.9},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.1","shortVersion":"4.52.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"圣诺生物(688117)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供圣诺生物(688117)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"圣诺生物,688117,圣诺生物股票,圣诺生物股票老虎,圣诺生物股票老虎国际,圣诺生物行情,圣诺生物股票行情,圣诺生物股价,圣诺生物股市,圣诺生物股票价格,圣诺生物股票交易,圣诺生物股票购买,圣诺生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"圣诺生物(688117)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供圣诺生物(688117)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}